Capex / expansionFiled on NSE ·
The Grob Tea Company approves ₹16 crore Capex for subsidiary's tea machinery
₹16 CrCapex / expansion
Key highlights
- Wholly-owned subsidiary M/s Bazaloni Group Limited approved ₹16 crore Capex on 12 Nov 2026
- Capex for installation of Orthodox Tea Manufacturing Machinery, expected completion by 30 Apr 2027
- Financing via subsidiary's bank borrowings; no direct financial input from The Grob Tea Company Limited
Original filing
General Updates
Read the filing on NSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Rossell Techsys
Aerospace & Defense
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from The Grob Tea Co
Other capex / expansion filings this fortnight
- Capex / expansionAlmondz Global SecuritiesAlmondz Global Securities' Associate PGIPL Secures 12.82 Cr Litres Ethanol Allocation for ESY 2026-27
- Capex / expansionInsolation EnergyInsolation Energy Limited reports Q2FY27 and H1FY27 results with strong revenue growth
- Capex / expansionSolarworld Energy SolutionsSolarworld Energy Solutions reports Q2 & H1 FY27 results, JV for solar cell plant approved
- Capex / expansionBench Mark Infotech ServicesBench Mark Infotech Services plans ₹100 crore investment in GPU-as-a-Service expansion
- Capex / expansionModi NaturalsModi Naturals Limited's subsidiary starts operations at expanded ethanol plant
- Capex / expansionUflexUflex Limited reports unaudited standalone and consolidated Q2 & H1 FY2026 results
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.